EP3384049
AÐFERÐIR VIÐ AÐ TENGJA ERFÐATILBRIGÐI KLÍNÍSKUM NIÐURSTÖÐUM HJÁ SJÚKLINGUM SEM ÞJÁST AF ALDURSTENGDRI SJÓNDEPILSHRÖRNUN SEM MEÐHÖNDLUÐ ER MEÐ AND-VEGF
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
1.12.2016EP published:
2.8.2023EP application number:
16823372.4
EP translation filed:
12.9.2023Grant published:
15.11.2023EPO information:
European Patent Register
Max expiry date:
30.11.2036Expiry date:
30.11.2026Next due date:
30.12.2026
Title in English:
METHODS OF ASSOCIATING GENETIC VARIANTS WITH A CLINICAL OUTCOME IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTI-VEGFLanguage of the patent:
English
Timeline
Today
1.12.2016EP application
2.8.2023EP Publication
12.9.2023Translation submitted
15.11.2023Registration published
30.11.2026Expires
Owner
Name:
Regeneron Pharmaceuticals, Inc.Address:
777 Old Saw Mill River Road, Tarrytown, NY 10591, US
Inventor
Name:
PERLEE, LorahAddress:
Tarrytown, NY 10591, US
Name:
HAMON, SaraAddress:
Tarrytown, NY 10591, US
Name:
PAULDING, CharlesAddress:
Tarrytown, NY 10591, US
Agent
Name:
Tego IP ehf.Address:
Pósthólf 8129, 128, Reykjavík,
Priority
Number:
201562262589 PDate:
3.12.2015Country:
US
Number:
201662291274 PDate:
4.2.2016Country:
US
Classification
Categories:
C12Q 1/6883
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 29.11.2023
Expires: 30.11.2024
Payer: Árnason Faktor ehf.
Number: 9
Paid: 21.11.2024
Expires: 30.11.2025
Payer: Árnason Faktor ehf.
Number: 10
Paid: 5.12.2025
Expires: 30.11.2026
Payer: Árnason Faktor ehf.